As such, our aim to investigate the efficacy of buformin in various models of erbB-2-overexpressing breast cancer, which accounts for approximately 30% of human breast cancer cases [46], has provided further evidence of the anti-cancer potential of buformin. The gene discussed is ERBB2; the disease is cancer.